2013
DOI: 10.18632/aging.100533
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Chronic treatment of mice with an enterically released formulation of rapamycin (eRapa) extends median and maximum life span, partly by attenuating cancer. The mechanistic basis of this response is not known. To gain a better understanding of these in vivo effects, we used a defined preclinical model of neuroendocrine cancer, Rb1+/− mice. Previous results showed that diet restriction (DR) had minimal or no effect on the lifespan of Rb1+/− mice, suggesting that the beneficial response to DR is dependent on pRb1… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
59
0

Year Published

2013
2013
2015
2015

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 73 publications
(61 citation statements)
references
References 35 publications
(71 reference statements)
2
59
0
Order By: Relevance
“…We showed that reduced neoplasia is an eRapa‐mediated longevity extension mechanism in spontaneous neoplasia models (Livi et al ., 2013; Hasty et al ., 2014) and potentially in wild‐type mice (Miller et al ., 2011). T cells and IFN‐γ mediate cancer immune surveillance (Mittal et al ., 2014).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…We showed that reduced neoplasia is an eRapa‐mediated longevity extension mechanism in spontaneous neoplasia models (Livi et al ., 2013; Hasty et al ., 2014) and potentially in wild‐type mice (Miller et al ., 2011). T cells and IFN‐γ mediate cancer immune surveillance (Mittal et al ., 2014).…”
Section: Resultsmentioning
confidence: 99%
“…We previously demonstrated significant lifespan extension in neoplasia‐prone Rb +/− and Apc Min/+ mice (Livi et al ., 2013; Hasty et al ., 2014). We interpret the eRapa‐mediated 3.3‐ to 12‐fold augmented lifespan extension of IFN‐γ −/− and RAG2 −/− mice versus modest lifespan extension in syngeneic BL6 mice (Zhang et al ., 2014) as consistent with cancer and infection prevention as lifespan extension mechanisms of eRapa, seen in exaggerated form in these mice that are highly susceptible to cancers and infections.…”
Section: Discussionmentioning
confidence: 99%
“…For example, if rapamycin suppresses aging, it will prevent any cancer including those with p53 and Rb mutations or ErbB activation. In fact, rapamycin prevents cancer in p53-deficient and Rb-deficient mice 150 - 153 as well as common cancers in normal mice 154 - 160 . Metformin, which affects the mTOR pathway and slows aging, also prevents a variety of cancers 161 - 165 .…”
Section: Cancer Preventionmentioning
confidence: 99%
“…Thus, the current data show that increased longevity is associated with little change in end-of-life pathology. Because cancer is the primary cause of death in UM-HET3 and C57BL (14)(15)(16)(17).…”
Section: A Comprehensive Assessment Of Aging In Micementioning
confidence: 99%